Sarilumab, an additional FDA-approved anti-IL-6Rα mAb for RA, which blocks both membrane-bound and soluble IL-6Rα, is under current Phase I and II clinical investigation in combination with capecitabine in stage I-III TNBC and metastatic TNBC patients (NCT04333706). Here, IL6R is linked to rheumatoid arthritis.